新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » BIOON报道 » Ultragenyx获取一项治疗罕见病二期研究项目

Ultragenyx获取一项治疗罕见病二期研究项目

来源:生物谷 2013-09-10 20:38

2013年9月10日讯 /生物谷BIOON/ --位于加州诺瓦托市的Ultragenyx医疗公司从日本Kyowa Hakko Kirin公司(KHK)获得了一项关于罕见骨科疾病的二期研究项目。公司将与Emil Kakkis公司联合开发这种用于治疗骨软化症的药物KRN23。KRN23是一种专门为治疗这种疾病而设计的抗体。目前处于二期研究中。同时,KHK公司也将保留一部分KRN23的所有权。(生物谷Bioon.com)

详细英文报道:

Flush from raising more than $100 million, Novato, CA-based startup Ultragenyx Pharmaceutical has stepped up with a new pact to partner on a rare bone-disease drug from Japan's Kyowa Hakko Kirin.

Under the guiding hand of BioMarin veteran Emil Kakkis, Ultragenyx will step in to co-develop KRN23, an antibody designed to treat X-linked hypophosphatemia which is now wrapping a Phase I/II study at KHK. Ultragenyx will now take over development responsibilities, while sharing costs with the Japanese pharma as they take aim at the U.S., Canadian and European markets.

"The collaboration combines KHK's broad antibody-based discovery, manufacturing and development capabilities with our expertise in the clinical development of novel therapeutics for rare genetic diseases," says Kakkis in a statement. "We look forward to working closely with the KHK team, investigators, and patients on continuing development of KRN23, a much-needed new therapy for XLH patients."

Launched only two years ago with a $45 million A round from TPG Biotech, Fidelity Biosciences, Europe's HealthCap and Pappas Ventures, Ultragenyx has been growing at a rapid pace. Its latest pipeline update now includes an impressive slate of four mid-stage programs for rare diseases, with one early-stage effort and more waiting in the preclinical wings.

XLH is a rare ailment triggered by inadequate mineralization of bone that can cause short stature and various abnormalities. The standard treatment today is oral phosphate replacement and vitamin D (calcitriol) therapy, which the biotech says is poorly tolerated and only partially effective at restoring bone physiology and growth.

KRN 23--which has completed several early-stage studies--works by binding to inhibiting fibroblast growth factor 23, a hormone that promotes phosphate excretion by the kidney and suppresses vitamin D production.

 

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库